(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.41%) $924.25
(0.32%) $0.935
(0.80%) $11.04
(0.13%) $0.800
(-0.32%) $91.87
5 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.08%
@ $21.78
Issued: 14 Feb 2024 @ 13:47
Return: 4.39%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: -1.94 %
Live Chart Being Loaded With Signals
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...
Stats | |
---|---|
Today's Volume | 137 278 |
Average Volume | 395 485 |
Market Cap | 964.47M |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-1.260 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.47 |
ATR14 | $0.0330 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
INSIDER POWER |
---|
72.48 |
Last 94 transactions |
Buy: 1 498 500 | Sell: 230 741 |
Volume Correlation
Bicycle Therapeutics PLC Correlation
10 Most Positive Correlations | |
---|---|
BHTG | 0.97 |
TENX | 0.967 |
GSMG | 0.966 |
GRNA | 0.958 |
SIRI | 0.954 |
SINT | 0.953 |
JAGX | 0.951 |
VWE | 0.951 |
DBGI | 0.948 |
NAKD | 0.948 |
10 Most Negative Correlations | |
---|---|
INTA | -0.972 |
GXII | -0.97 |
TETC | -0.968 |
CRZN | -0.963 |
AGGR | -0.963 |
MSDAU | -0.962 |
TBSAU | -0.962 |
LDHA | -0.962 |
HERA | -0.961 |
MSDA | -0.961 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bicycle Therapeutics PLC Correlation - Currency/Commodity
Bicycle Therapeutics PLC Financials
Annual | 2023 |
Revenue: | $26.98M |
Gross Profit: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2023 |
Revenue: | $26.98M |
Gross Profit: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2022 |
Revenue: | $14.46M |
Gross Profit: | $10.78M (74.51 %) |
EPS: | $-3.80 |
FY | 2021 |
Revenue: | $11.70M |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bicycle Therapeutics PLC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators